ClearPoint Neuro Inc. (CLPT)
CLPT trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1285550/000119312526111231/0001193125-26-111231-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CLPT on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001285550 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $37.0M |
| Net income | -$25.5M |
| Operating income | -$24.2M |
| Net margin | -69.1% |
| Operating margin | -65.4% |
| Revenue growth | +17.8% |
| Cash | $45.9M |
| Total assets | $97.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-28 |
| Cash and burn | $46.2M cash; operating cash flow -$11.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 32,054,268 (2026-10-21); 28,423,308 a year earlier; 24,620,567 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-01-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $12.1M | -$7.5M | -$20.1M | $46.2M | $50.8M | $45.5M | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $10.9M | -$11.3M | -$7.0M | $29.4M | $50.2M | $42.3M | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $12.1M | -$9.6M | -$8.0M | $35.6M | $49.6M | $40.6M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $10.4M | -$7.8M | -$12.1M | $45.9M | $49.1M | $37.0M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $8.9M | -$5.9M | -$3.1M | $38.2M | $29.2M | $34.3M | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $9.2M | -$5.8M | -$2.6M | $41.5M | $28.8M | $33.6M | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $8.5M | -$6.0M | -$6.2M | $12.4M | No debt tags | $32.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $7.8M | -$5.4M | -$1.2M | $20.1M | No debt tags | $31.4M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-01-22 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-10-28 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.4% |
| 1 month | -13.6% |
| 3 months | -45.0% |
| Year to date | -38.0% |
| 1 year | -45.3% |
| From 52-week high | -56.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PROF | Profound Medical Corp. | $7.34 | -1.08% | $268.8M |
| SSII | SS Innovations International Inc. | $1.35 | -18.67% | $270.7M |
| NPCE | Neuropace Inc. | $7.97 | +5.42% | $274.6M |
| OFIX | Orthofix Medical Inc. Common Stock (DE) | $6.80 | -5.16% | $277.2M |
| OSUR | OraSure Technologies Inc. | $3.60 | -0.55% | $248.6M |
| TMCI | Treace Medical Concepts Inc. | $4.42 | -16.13% | $289.8M |
| INFU | InfuSystems Holdings Inc. | $14.79 | +0.48% | $296.3M |
| PDEX | Pro-Dex Inc. | $64.48 | -1.80% | $206.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier